Macrophage-based therapy
Autologous non-polarized human macrophages administered intravenously address the limitations of current liver cirrhosis treatments by reducing fibrosis and enhancing liver function, offering a viable alternative to transplantation.
Patent Information
- Application Number
- JP2024152332
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2018-03-16
- Filing Date
- 2024-09-04
- Publication Date
- 2024-11-28
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current treatments for liver cirrhosis, such as liver transplantation, are limited by donor organ availability and require lifelong immunosuppression, while alternative therapies to prevent or delay the progression to the decompensated terminal phase are urgently needed.
Administration of autologous, non-polarized human macrophages derived from monocytes, characterized by high expression of markers like 25F9 and CD206, and incubated with M-CSF to enhance their therapeutic potential, administered intravenously to treat liver cirrhosis.
The treatment reduces fibrosis, improves liver function, and promotes hepatocyte regeneration, as evidenced by changes in MELD scores and liver fibrosis markers, indicating improved liver health and function.
Smart Images

Figure 2024166223000012 
Figure 2024166223000013 
Figure 2024166223000014
Abstract
Description
[Technical field]
[0001] Liver cirrhosis is a major health problem in the Western world. In the UK, liver disease is the fifth leading cause of death, and over one million deaths in 2010 were estimated to be a result of cirrhosis. The disease is associated with high levels of morbidity due to progressive tissue damage, fibrotic scarring, and loss of liver function, and the only treatment option for end-stage disease is liver transplantation. However, the availability of donor organs cannot meet the demand, and patients with end-stage liver disease are often not suitable for transplantation. Transplant recipients require lifelong immunosuppression with associated increased health risks. In 2015, 611 patients were reported to be on the UK living donor liver transplant list. Patients may wait up to two years before receiving a liver transplant. At one year after registration, 17% of patients were still on the liver transplant list. Similarly, in the US, there are many patients on the liver transplant waiting list (LTWL) who may not be able to identify a donor organ. Approximately 1700 patients die on the waiting list each year or are removed from the list due to deteriorating health, while approximately 6500 remain on the list for more than six months. Treatment of end-stage liver disease has become a major concern worldwide. [Background technology]
[0002] There is an urgent need for alternative therapies to prevent or delay the progression of liver disease to the end-stage of decompensation.
[0003] The pathology of liver cirrhosis is driven by a number of causative factors, such as high alcohol consumption, obesity, metabolic disorders, viral infections, or autoimmune diseases, and healthy liver cell tissue and liver architecture are gradually lost and replaced by myofibroblast-derived fibrotic scars. It is increasingly recognized that liver fibrosis is at least partially reversible and liver regeneration is possible when factors that promote liver damage, such as alcohol and viruses, are eliminated.
[0004] Animal models of liver regeneration after experimental liver injury indicate that macrophages may play an important role in the control and repair of fibrotic liver disease. Hepatic macrophages are a heterogeneous population of cells, including resident Kupffer cells and recruited hematopoietic-derived macrophages, and have diverse roles in the liver's regenerative response after injury, including phagocytosis, maintaining immune tolerance, both promoting and resolving inflammation and fibrosis via hepatic stellate cell activation / cytokine production, and extracellular matrix degradation.
[0005] Several macrophage-directed therapeutic approaches to liver diseases have been reported (e.g., as reviewed in Tacke et al., J. Hepatology 2017;66:1300-1312), but face various challenges due to the complex nature of phage functions and interactions in macropathology. Moreover, macrophage subsets can exert completely opposing functions, suggesting that therapeutic intervention requires careful consideration and establishment of the specific properties of administered macrophages, as well as their optimal dosage and timing. Summary of the Invention [Problem to be solved by the invention]
[0006] The administration of non-polarized monocyte-derived mature macrophages in humans and their efficacy in treating liver cirrhosis has not previously been evaluated. [Means for solving the problem]
[0007] Thus, in a first aspect, the present invention provides autologous isolated non-polarized human macrophages for use in the treatment of liver disease.
[0008] In some embodiments, the non-polarized human macrophages for use according to any aspect or embodiment of the invention are derived from monocytes. In some embodiments, the non-polarized human macrophages for use according to any aspect or embodiment of the invention are mature macrophages. Suitably, the macrophages for use according to the invention are characterized by high or elevated expression of at least one macrophage-associated surface marker, such as 25F9 or CD206; in some embodiments, the expression is "high" or "elevated" compared to the expression levels of these markers on source cells, such as progenitor cells or freshly isolated peripheral blood monocytes. Other surface markers include the presence and / or high expression of one or more of CD163 or CD169. In some embodiments, a lack of CD93 and a reduction in the inflammatory cytokine receptor CCR2 can be detected compared to isolated CD14+ monocytes on day 0. In certain embodiments, non-polarized macrophages are characterized by positive expression of CD45 / CD14, have a viability of greater than 80%, and have an MFI (mean fluorescence intensity) for surface markers 25F9 and CD206 that is 5-fold higher than the MFI of the original monocytes on day 0.
[0009] In one embodiment, autologous isolated non-polarized human macrophages for use according to any aspect or embodiment of the invention are prepared from CD14+ monocytes isolated from peripheral blood of an affected patient. Suitably, these CD14+ monocytes are incubated with M-CSF for at least 48 hours, or for 3-5 days, or for 7 days. In some embodiments, M-CSF is used at a concentration of about 100 ng / ml, although it will be understood that this may be varied to obtain non-polarized macrophages with desired characteristics. In one embodiment, non-polarized macrophages for use according to any aspect or embodiment of the invention are obtained or obtainable by a process as described in the Examples herein. In particular, the process is as described in Example 4A or Example 4B herein. In a further aspect, the invention provides autologous macrophages obtained or obtainable by a process as described in Example 4A or Example 4B. In some embodiments, the monocytes are incubated in T cell medium as described herein.
[0010] In some embodiments, the autologous isolated non-polarized human macrophages according to the present invention are for use in liver cirrhosis, preferably the liver cirrhosis is caused by either high alcohol consumption, obesity, metabolic disorders or viral infection, most preferably alcohol-induced cirrhosis, NASH or HCV.
[0011] In other embodiments, the autologous isolated non-polarized human macrophages are for intravenous administration. Suitably, the dose is approximately 10 7 From 10 9 Cells, suitably at least 10 7 Cells, at least 10 8 Or at least 10 9 Multiple doses may be administered.
[0012] In another aspect of the present invention, a macrophage is provided for use in a method for treating fibrosis, preferably liver cirrhosis, by administering one or more doses of said macrophage to a human in need thereof. In one embodiment, one, two, three or more doses of said macrophage are administered to a human in need thereof, with an interval of approximately one month between each of said doses. In one embodiment, the first dose is on day 1, the second dose is on day 30, and the third dose is on day 60. In one embodiment, the macrophage is included in a pharmaceutical composition. In one embodiment, administration of said macrophage results in a reduction of fibrosis.
[0013] In some embodiments, the human in need thereof has a cirrhotic liver disease. Suitably, the human is an affected patient with a MELD score of 10-16.
[0014] The number of macrophages in each dose can vary depending on the individual being treated. In some embodiments, each dose contains at least 1 x 10 macrophages per dose. 7 Macrophages, suitably 1 × 10 8 Or 1×10 9 Includes macrophages.
[0015] In one embodiment, administration of each dose is by intravenous administration. Suitably, intravenous administration is via a peripheral vein.
[0016] Macrophages for use in the method according to this aspect of the invention are preferably in a non-polarized state. Suitably, such macrophages are characterized by a higher expression of 25F9 or CD206 than that found in the monocytes from which they are derived. In some embodiments, the non-polarized macrophages are derived from a person's own PBMCs, i.e., autologous. In other embodiments, the non-polarized macrophages may be allogeneic, e.g., derived from a healthy donor for administration to a patient with a relevant disease. In other embodiments, the non-polarized macrophages may be derived from stem cell bone marrow (BM), embryonic stem cells (ESCs) or induced pluripotent stem cells (iPSCs). Methods for generating suitable macrophages are described herein.
[0017] In another aspect, the present invention provides a method for administering up to 10 doses of 30 mg of 10 ... 9 Provided is an autologous macrophage for use in a method for treating liver cirrhosis by intravenous administration of cells. Suitably, these doses are provided at approximately monthly intervals or approximately 30 days intervals. In some embodiments, the use involving autologous macrophages according to the present invention can be combined with another drug or anti-fibrotic agent used to treat liver cirrhosis. In some embodiments, the other drug can be G-CSF, such as recombinant human G-CSF.
[0018] Other aspects and embodiments of any of the aspects of the present invention are set out in the following numbered paragraphs:
[0019] 1. A method for preparing autologous isolated non-polarized human macrophages, comprising: a) isolating monocytes from the peripheral blood of a patient, suitably an affected human patient; b) incubating the isolated monocytes in a medium containing 50 to 150 ng / ml M-CSF for at least 48 hours; A method comprising:
[0020] 2. The method according to item 1, wherein the isolated monocytes are incubated with 100 ng / mL M-CSF.
[0021] 3. The method according to item 1 or item 2, wherein the isolated monocytes are incubated in a culture bag.
[0022] 4. The method according to any of items 1 to 3, wherein the isolated monocytes are incubated with M-CSF for 7 days.
[0023] 5. Isolated monocytes are cultured at 1 cm 2 per ml and 2 x 10 6 The method according to any one of items 1 to 4, wherein the monocytes are incubated at a density of 100 μg / ml or more.
[0024] 6. The method according to any of items 1 to 5, wherein the monocytes are characterized by surface expression of CD14.
[0025] 7. The method according to any of items 1 to 6, wherein monocytes are isolated using CD14 microbead selection.
[0026] 8. The method according to any of items 1 to 7, wherein after incubation with M-CSF, the autologous isolated non-polarized human macrophages are characterized by positive expression of CD45 / CD14, have a viability of more than 80% and have an MFI (mean fluorescence intensity) for the surface markers 25F9 and CD206 that is more than 5-fold higher than the MFI of the original monocytes on day 0.
[0027] 9. The method according to any of items 1 to 8, wherein the affected patient has cirrhosis.
[0028] 10. The method according to item 9, wherein the cirrhosis is caused by either high alcohol consumption, obesity, metabolic disorders or viral infections.
[0029] 11. A preparation of autologous non-polarized human macrophages for administration to an affected patient, comprising: a) non-polarized human macrophages produced according to any of the methods of items 1 to 10; b) Excipients and Including, c) the non-polarized human macrophages exhibit high expression of at least one surface marker selected from 25F9, CD206, CD163, CD169 or a combination thereof, and / or d) The formulation has a concentration of at least 1 × 10 7 and / or e) the preparation is formulated as an infusion solution for intravenous or subcutaneous administration; and / or f) the formulation contains less than 4.5% v / v serum; formulation.
[0030] 12. The formulation according to item 11, wherein the excipient comprises 0.9% v / v saline with 0.5% v / v human serum albumin.
[0031] 13. A method of treating liver disease in humans by administration of autologous isolated non-polarized human macrophages.
[0032] 14. The method according to item 13, wherein the non-polarized human macrophages are derived from monocytes.
[0033] 15. The method according to any of items 13 to 14, wherein the non-polarized human macrophages have increased expression of 25F9 or CD206 compared to the source cells.
[0034] 16. The method according to any of items 13 to 15, wherein non-polarized human macrophages are prepared according to the method according to any of items 1 to 10.
[0035] 17. The method according to any of items 13 to 16, wherein the administration is preferably by intravenous injection.
[0036] 18. The method according to item 17, wherein the injection is via a peripheral vein.
[0037] 19. Administration or injection is 10 7 ~10 9 18. The method according to any of items 13 to 17, wherein the dose is intracellular.
[0038] 20. The method according to item 19, wherein the patient receives three injections at monthly intervals.
[0039] 21. The method according to any of items 13 to 19, wherein the patient has a MELD score of 10 to 16.
[0040] 22. A method for treating liver disease in a patient having a MELD score of 10 to 16, comprising administering a therapeutically effective amount of a) autologous macrophages prepared according to the method described in any one of items 1 to 10, and b) an anti-fibrotic agent and / or G-CSF.
[0041] 23. A method for promoting hepatocyte regeneration in the liver, comprising administering to a patient an effective amount of autologous isolated non-polarized human macrophages.
[0042] 24. The method according to item 23, wherein the administration is intravenous, preferably via a peripheral vein.
[0043] 25. The method according to item 23 or item 24, wherein the patient has alcohol-induced cirrhosis.
[0044] 26. 10 per dose 7 From 10 9 26. The method of any of items 23 to 25, wherein autologous cells of the present invention are administered. [Brief description of the drawings]
[0045] [Figure 1]Initial optimization of GMP macrophage cultures from normal donors. A) CliniMACS CD14 bead isolation of monocytes using LS columns produced a highly purified CD14 fraction (n=26). B) CliniMACS Prodigy CD14 selection produced a comparably enriched CD14+ fraction from apheresis samples from cirrhotic volunteers. C) Cirrhotic patients showed a trend towards higher CD14 counts in peripheral blood (n=11, p=0.108). D) Although not significant, TexMACS resulted in the highest and most consistent yield of macrophages (n=6-10). E) Macrophages from TexMACS cultures were significantly larger in size than those cultured in AIM-V medium (p<0.0001, n=5). F) GMP grade M-CSF from R&D produced similar macrophage yields as standard M-CSF, but with stronger expression of the macrophage marker 25F9 (n=6). G) Microscopic images show that DMEM+5%AB produced aggregation and adherence in macrophage cultures unlike those produced in defined media. (Fraser et al., Cytotherapy 2017;19(9):1113-1124). [Diagram 2] Figure 1 shows the phenotype of fresh and frozen monocytes from GMP macrophages. Buffy coat monocytes were isolated, an aliquot was frozen and stored in LN2, and the remainder was used to generate macrophages. After thawing, monocytes were cultured to macrophages and the phenotypes were compared. Many markers were unchanged in macrophages generated from thawed monocytes, but CD206 and CD163 were significantly decreased and CCR2 was significantly increased in macrophages from frozen monocytes (n = 10). [Diagram 3] Phagocytosis of monocytes and macrophages. (A) Bright field / fluorescein isothiocyanate fluorescence EVOS images (magnification x100) showing uptake of pHRodo beads. (B) Quantification of uptake shows no significant difference in uptake of beads by monocytes or macrophages and no difference in the number of beads taken up (n = 4). Data are presented as mean ± SD. [Figure 4]Microscopic and phenotypic changes of polarized macrophages. A) EVOS brightfield images (magnification x400) of polarized macrophages showing clear differences in morphology between angular pointed M1 / M (IFNg) and elongated smooth spindle shaped M2 / M (IL-4) macrophages. B) Flow cytometry analysis shows no significant differences in macrophage marker 25F9, however IL-4 stimulated macrophages significantly increase CD206 expression, whereas IFN-g treated macrophages decrease it (n=5, mean + / - sd, p<0.05). [Diagram 5] Figure 1 shows secretome analysis of macrophages from healthy donors. Day 7 macrophages (n=3) were untreated or stimulated with TNF-α and poly I:C (PIC) or IFNg and LPS for 12 h and analyzed by BioRad multiplex ELISA. Both IL-10 (A) and IL-1Ra (B) were significantly upregulated by TNF-α / PIC, as was VEGF (D). IL-12p40 levels (C) were not affected by TNF-α / PIC, but were significantly increased by LPS / IFN-g. Data are presented as mean + sd, * p<0.05. [Figure 6] Graph showing a phenotypic panel of clinical grade macrophages (n=7) taken from patients with cirrhosis. A) Release criteria showing increased MFI between monocytes at day 0 and macrophages at day 7. B) Extended panel including two additional scavenger receptors (CD163 / CD169) and markers of macrophage migration. Note that there was one outlier in the day 7 data for CCR2, which was removed from the analysis after Grubb test (●). Data are expressed as mean + / -, p<0.05. [Figure 7]Graphs showing the stability of macrophages from GMP cirrhosis patients. A) Viability shows no significant decline even after 48 hours at room temperature. B) 25F9 expression steadily declines over time, but even at 48 hours remains well above the 5-fold increase required for efficacy. C) CD206 remains high until approximately 24-30 hours after collection, then declines more rapidly, but still remains well above the 5-fold threshold established in the study criteria (n=3). [Figure 8-1] Figure 8. Genetic changes in apheresis-derived monocytes on day 0 and after differentiation on day 7 in healthy volunteers (n=5) and patients with liver cirrhosis (n=8) (ns, not significant, *P<0.05, mean and SEM). (Moore JK et al., Cytotherapy. 2015; 17(11):1604-16). [Figure 8-2] Continued from Figure 8. [Figure 9] Graph showing the mean ΔMELD for all patients in the MATCH study. d360 data for patient 9, patient 10, and patient 11 are not included. [Figure 10] Graph showing mean ΔMELD for MATCH patients and the contributions of the three components: BIL, CRE and INR. d360 data for patient 9, patient 10 and patient 11 are not included. [Figure 11] Graph showing the ELF scores for all patients in the MATCH study. [Figure 12] 4 is a graph showing the ΔELF of all patients in the MATCH study. [Figure 13] Graph showing HA levels for all patients in the MATCH study. [Figure 14] 13 is a graph showing PNIIIP values for all patients in the MATCH study. [Figure 15] Graph showing TIMP1 levels for all patients in the MATCH study. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0046] Macrophages Macrophages are phagocytes of two different origins - tissue-resident macrophages, derived from fetal cells and distributed throughout all tissues in the body, and peripheral blood monocyte-derived macrophages, which can differentiate in response to signals such as injury, inflammation, and disease. Monocyte-derived macrophages have a wide range of context-dependent functions and are involved in controlling infectious organisms, removing damaged cells, and repairing tissues. The early classification of macrophages into M1 (classically activated, pro-inflammatory) and M2 (alternatively activated, anti-inflammatory) is considered an oversimplification, and macrophages can have both pro- and re-resolution functions depending on the activation method and cytokine environment, as described, for example, in Murray et al. (Immunity 2014; 41:14-20) and Tacke et al. (J. Hepatology 2017; 66:1300-1312).
[0047] In the liver, macrophages can promote fibrogenesis by activating the profibrotic cytokine transforming growth factor (TGF)-β and by stimulating myofibroblast proliferation via platelet-derived growth factor (PDGF), IL-1β, and tumor necrosis factor-α. They are also important for the resolution of fibrosis, as they provide a rich source of scar-degrading matrix metalloproteinases (MMPs). They produce factors such as MMP-9 that promote hepatic stellate cell apoptosis, which is necessary for the resolution of scar. They also phagocytose cellular debris and eliminate potential proinflammatory signals. The wide variety of responses is reviewed, for example, by Tacke et al. (J. Hepatology 2017; 66:1300-1312).
[0048] Cirrhotic donors have a high number of circulating monocytes, typically >30% of total nucleated cells (TNC), significantly greater than reported values for healthy donors or patients donating CD14 treatment (Campbell et al., Methods Mol Med. 2005; 109:55-70), which correlates closely with disease progression (Zimmermann et al., PLoS One 2010; 5(6):e11049). However, it has not been previously established that monocytes isolated from cirrhotic patients can differentiate into functional macrophages comparable to those from healthy volunteers. The data presented herein report no significant changes between the function of macrophages derived from cirrhotic patients and healthy volunteers, indicating that ex vivo maturation of circulating monocytes may be a technique to generate therapeutic mature macrophages for clinical cell therapy. Advantageously, therefore, the use of autologous cells, i.e., the cirrhotic patient's own cells, is provided, minimizing the risk of bioincompatibility and immune reactions from cell therapy. Furthermore, a very high initial number of target cells may reduce the overall selection efficiency due to excessive reagent and selection column volumes.Despite the high monocyte numbers in cirrhotic patients, the CliniMACS Prodigy system was surprisingly able to reproducibly isolate enough cells to meet the manufacturing standard of at least 40% CD14+ cell yield.
[0049] As described herein, monocytes are cultured in a GMP-compliant, antibiotic-free defined medium, producing a conversion rate to macrophages of approximately 45%. The culture conditions are different from previous prior art.
[0050] Non-polarized macrophages Suitably, a "non-polarized macrophage" according to the present invention is a mature macrophage (i.e. fully differentiated from a source macrophage precursor or progenitor cell such as a monocyte), but is not polarized (i.e. has not received further stimuli that induce a specific functional capability). Non-polarized macrophages may also be described as "naive" or "non-activated".
[0051] In one embodiment of any aspect of the invention, the non-polarized macrophages are monocyte-derived cells. Thus, the non-polarized macrophages may be derived, for example, by leukapheresis or from peripheral blood mononuclear cells (PBMCs) removed from a blood sample and by isolating and culturing the mononuclear cells. Suitably, the monocytic cells are CD14+ cells that can be isolated by selecting for CD14 expression. Suitable methods are described herein and may include magnetic microbead selection.
[0052] In some embodiments, PBMCs are removed from the patient to be treated in order to obtain patient-derived monocytes capable of generating autologous non-polarized macrophages. Suitable methods for removing PBMCs from patients are described, for example, herein. The advantageous use of autologous cells avoids problems faced from non-autologous approaches, such as the introduction of exogenous bacteria or viruses, bioincompatibility and immune rejection. In other embodiments, the non-polarized macrophages may be allogeneic, i.e. derived from monocytes obtained from a healthy donor. Suitably, the healthy donor is matched, e.g. HLA type matched. Briefly, the method for generating non-polarized macrophages comprises culturing CD14+ monocytes isolated from PBMCs in the presence of M-CSF to generate mature macrophages. Suitably, the isolated monocytes may be incubated for at least 48 hours or more, e.g. 3 days or more, preferably 7 days. In some embodiments, the patient-derived PBMCs may be maintained for a period of time, e.g. overnight, before being processed or cultured to generate mature non-polarized macrophages. In some embodiments, the isolated cells may be provided in a culture bag.
[0053] In some embodiments, the non-polarized macrophages are generated from patient-derived monocytes according to the culture methods and conditions described in the Examples section herein. In some embodiments, the culture medium is any medium suitable for generating those non-polarized macrophages from the source cells. The medium may be serum-free. Suitably, the medium is a chemically defined medium, such as a Good Manufacturing Practice (GMP) compliant defined medium supplemented with an appropriate concentration of M-CSF. In some embodiments, the M-CSF may be recombinant M-CSF, preferably recombinant human M-CSF. Advantageously and surprisingly, the medium is not a medium specifically optimized for macrophages, but a medium optimized for the culture and expansion of T cells. In one embodiment, the medium is TexMAC (Miltenyi) or AIM-V (Thermofisher).
[0054] Suitably, the concentration of M-CSF is 50-150 ng / ml, for example 100 ng / ml. In some embodiments, the method of preparing autologous non-polarized macrophages generates a population of non-polarized macrophages with a viability of greater than 80%, which may be measured by methods well known to those skilled in the art, such as DRAQ7 staining as described herein.
[0055] Suitably, non-polarized mature macrophages are characterized by elevated expression of at least one or both of the surface markers "25F9" and CD206. "Elevated" expression refers to expression that is increased compared to the expression of these markers in source macrophage precursor or progenitor cells such as monocytes (e.g. isolated day 0 / naive monocytes). In some embodiments, "elevated" expression refers to expression of a surface marker that is at least approximately 5-fold higher compared to the source cells. Expression of the marker may be determined by methods known to those skilled in the art, including fluorescent labeling techniques as described herein. Suitably, the level or expression may be measured by mean fluorescence intensity (MFI) using the methods described herein. 25F9 refers to a macrophage marker antibody provided by eBioscience / Thermofisher that recognizes a marker on mature macrophages but not immature macrophages or monocytes, or other blood cells. The marker to which the antibody binds is unknown; the name is derived from the antibody clone. More details are provided here (https: / / www.thermofisher.com / antibody / product / Mature-Macrophage-Marker-Antibody-clone-eBio25F9-25F9-Monoclonal / 50-0115-41). In some embodiments, a label, such as an antibody that competes with 25F9 for binding to the same surface marker, may also be used to identify non-polarized macrophage phenotype. As used herein, "expression of 25F9" refers to the expression of a marker to which 25F9 binds.
[0056] In some embodiments, the source monocytes are CD45 + , CD14 + , 25F9 - , CD206 - Incubation in an appropriate medium, such as medium containing M-CSF, induces the expression of CD45 + , CD14 + , 25F9 + , CD206 +In a further embodiment, these source monocytes also express CCR2 high , CD163 low , CD169 low Characterized by CCR2 mid , CD163 + , CD169 + They then mature into non-polarized macrophages characterized by
[0057] Other markers that may be increased in expression on "non-polarized macrophages" include increased levels of CD163 and CD 169, and decreased levels of CCR2. In some embodiments, non-polarized macrophages may be described as anti-inflammatory and / or anti-fibrotic due to the expression of certain surface markers or scavenger receptors involved in the clearance and uptake of damaged cells, fibrotic material, and pro-inflammatory cytokines. Macrophage nomenclature is reviewed, for example, in Martinez and Gordon (F1000Prime Rep. 2014; 6:13).
[0058] In some embodiments, non-polarized mature macrophages may be polarized to an M1 or M2-like phenotype by incubation with appropriate polarization factors, for example, M1 polarization may be obtained by incubation with INF-gamma or TLR agonists such as LPS or poly(I:C), while M2 polarization may be obtained by stimulation with IL4.
[0059] Non-polarized mature macrophages can be derived from stem cells such as embryonic stem cells (ES cells), human induced pluripotent stem cells (human iPSCs), and bone marrow-derived hematopoietic stem cells.
[0060] Various methods of producing macrophages from pluripotent stem cells such as ES cells and iPSCs are known in the art, see for example van Wilgenburg et al. (PLoS One 2013; 8(8):e71098). Methods for determining that the developed cell lines are pluripotent and have a normal karyotype are described, for example, in Yang et al. (Stem Cells 2017; 35(4):886-897). Suitable human induced pluripotent stem cell lines include SFCi55, for example, as described in co-pending application PCT / GB2017 / 052769.
[0061] A suitable method for generating macrophage progenitors from such human iPS cell lines is as follows: they were maintained in StemPro medium prepared by supplementing DMEM / F12 with Glutamax (Invitrogen) with StemPro supplement (Invitrogen), 1.8% BSA (Invitrogen), 0.1 mM β-mercaptoethanol (Invitrogen) and 20 ng / ml human basic FGF (Invitrogen). Methods for differentiating iPSCs into macrophages are described in van Wilgenburg et al. On day 0, spent medium was removed from one confluent well of a 6-well plate and replaced with 2 ml of StemPro (ThermoFisher) supplemented with cytokine mix 1 (50 ng / ml BMP4, 50 ng / ml VEGF, and 20 ng / ml SCF). Cells were dissected using an EZPassage™ tool and gently removed with a Pasteur pipette. 5 They were divided equally into two wells of an ultra-low attachment 6-well plate (Corning) and 2 ml of X-VIVO™ 15 medium containing cytokine mix 1 was added to each well. The cells were cultured in suspension for 3 days (supplemented with cytokines on day 2) to generate embryoid bodies (EBs). On day 4, EBs were lifted and transferred to gelatin-coated tissue culture grade 6-well plates in X-VIVO™ 15 medium supplemented with cytokine mix 2 (100 ng / ml M-CSF, 25 ng / ml IL3, 2 mM Glutamax, 1% penicillin / streptomycin, 0.055 M β-mercaptoethanol). Approximately 30 EBs were plated in each well. EBs were maintained in this medium for the remainder of the protocol, with spent medium being replaced with fresh medium every 3-4 days. After approximately 2 weeks, EBs generated macrophage progenitor cells in the culture supernatant, which were collected and transferred to 10 cm2 bacteriological dishes in X-VIVO™ 15 medium supplemented with cytokine mix 3 (100 ng / ml M-CSF, 2 mM Glutamax, 1% penicillin / streptomycin) and allowed to mature into iPSC-derived macrophages (iPSC-DMs) for 5-7 days. Macrophage progenitor cells could be collected twice weekly for approximately 2 months.
[0062] Other methods of generating macrophage progenitor cells are described in Yeung et al., Sci. Rep. 2015; 5: 8908, Zhuang et al., J Immunol Methods. 2012; 385 (1-2): 1-14, Sneju et al., Oncoimmunology 2014; 3(1): e27927, Hale et al., PLoS One 2015; 10(5): e0124307, Zhang et al., Circ Res. 2015; 117(1): 17-28, Mucci et al., Stem Cell Reports 2016; 7(2): 292-305 and van Wilgenburg et al., PLoS One 2013; 8(8): e71098.
[0063] ES cell-derived macrophages (ESDMs) can be generated by culturing ES cells in the presence of colony-stimulating factor-1 (CSF-1) (also known as M-CSF) and IL-3 to form embryoid bodies (EBs). The EBs adhere to tissue culture plastic, whereas the macrophage precursor cells are non-adherent and are released into the medium. The macrophage precursor cells can then be harvested at various time points, for example after 10 or 20 days, plated on untreated petri dishes, and cultured in the presence of CSF-1 alone. This process can give rise to monocyte-like cells that adhere to the plastic forming a monolayer and mature into ESDMs.
[0064] Maturation of ES cells into ESDMs can be monitored by detecting the presence of mature macrophage-specific markers, including 25F9 (human macrophage specific) and / or CD11b. Furthermore, human macrophages may be characterized by the absence of the monocyte marker CD93. Advantageously, the described method results in a substantially homogenous population of ESDMs.
[0065] Liver disease In some aspects or embodiments, the present invention provides treatment of liver disease in patients, particularly those suffering from liver damage resulting in liver fibrosis or cirrhosis. Chronic liver damage leads to scar deposition and loss of liver cells. Excessive accumulation of scar tissue leads to liver fibrosis. At this stage, the progression of fibrosis can be arrested. However, untreated fibrosis may eventually lead to cirrhosis. In some embodiments, the liver disease is one in which cirrhosis is caused by damage to liver cells, such as diseases of viral origin (including treated (sustained viral response) hepatitis C (HCV), hepatitis B), damage due to alcoholism (alcohol-related liver disease (ALD)), or diseases of liver cell origin, such as non-alcoholic steatohepatitis (NASH) (including diabetes or obesity-induced NASH), idiopathic cirrhosis, non-alcoholic fatty liver disease (NAFLD), including hemochromoptosis or alpha-1-antitrypsin deficiency. In some embodiments, the underlying etiology has been eliminated (eg, a patient suffering from damage due to alcoholism no longer drinks alcohol, or a patient suffering from damage due to HCV no longer has HCV, etc.).
[0066] Affected patients suitable for treatment or use according to any aspect or embodiment of the invention may be those with the relevant disease and severity.
[0067] treatment The term "treatment" as used herein refers to an intervention that reduces fibrosis in a subject, prevents progression, or partially or completely alleviates clinical symptoms associated with liver disease or injury. Suitably, treatment may result in increased or accelerated liver regeneration. Advantageously, the macrophages used according to the present invention provide anti-fibrotic and pro-regenerative cells.
[0068] Suitably, administration of non-polarized human macrophages in accordance with the present invention may result in one or more of the following beneficial effects: reduced fibrosis or reduced liver disease in a subject, reduced necrosis, increased hepatocyte proliferation, reduced levels of pro-inflammatory cytokines, increased phagocytosis at sites of fibrosis.
[0069] Liver disease is usually measured by the MELD (Measure of End-stage Liver Disease) score, a scoring system derived from serum markers blood bilirubin, creatinine, and coagulation activity. This scale was originally developed to predict mortality and is used to prioritize patients for liver transplantation. It predicts 3-month and 1-year mortality and predicts clinical decompensation in patients with compensated cirrhosis.
[0070] Changes in MELD are a more important determinant of death than initial MELD alone. For any given MELD, the magnitude and direction of change in MELD score over the previous 30 days is a significant independent predictor of mortality. MELD scores are used by all major Western regulatory agencies involved in liver transplantation (UK Transplant, Eurotransplant, UNOS) to help prioritize liver transplant allocation. In some embodiments, treatment with non-polarized human macrophages according to the present invention may result in a change in MELD in a subject. In other embodiments, treatment may result in a change in one of the liver-related components of the MELD score, namely bilirubin (BIL) and / or international normalized ratio (INR).
[0071] In other embodiments, treatment with non-polarized human macrophages according to the invention may result in a change in UKELD. Other methods for measuring effects in a subject include assessing changes in liver fibrosis measured by transient elastography, by using Enhanced Liver Fibrosis Test-ELISA, by measuring liver metabolism and regenerative activity using labeled metabolites and liver MRI scans, or by measuring liver volume and blood flow using MRI. In other embodiments, treatment with non-polarized human macrophages according to the invention may result in a change in ELF or one of the liver-related components of the ELF score, namely hyaluronic acid (HA), tissue inhibitor of metalloproteinase-1 (TIMP-1) and propeptide of procollagen type III (PIIINP). In other embodiments, epitopes such as disease-specific biomarkers and neoepitopes may be measured. For example, treatment with non-polarized human macrophages according to the invention may result in changes in the precisely cleaved N-terminal propeptide of collagen III (PRO-C3) and / or peptide of helical collagen III degradation (C3M). During fibril assembly, the N-terminal propeptide of collagen III is cleaved by the N-protease, but removal of the propeptide may be incomplete, so PIIINP may be a marker of both fibril formation and degradation, whereas PRO-C3 is a marker of formation, as PRO-C3 is specific for the N-protease cleavage site. For example, ELF, liver-related components of ELF, PRO-C3 and C3M may be measured according to any of the following publications: Thiele et al. (Gastroenterology 2018; 154: 1369-1379), Irvine K et al. (Liver International 2016, 370-377 ISSN 1478-3223), Barascuk N et al. (Clinical Biochemistry 34 (2010) 899-904), and Nielsen MJ et al. (Am J Transl Res 2013; 5 (3): 303-315).
[0072] The term "subject" as used herein refers to any individual who may benefit from the treatment of liver disorders. The subject may be a human subject, a person in need of treatment, such as a diseased patient. Suitably, the person suitable for treatment according to the present invention is one with cirrhotic liver disease, preferably a patient with a MELD score between 10 and 16. The person with liver disease may also be suitable for treatment, such as a person / patient with portal hypertension.
[0073] dose It will be appreciated that a therapeutically effective amount or dose of non-polarized macrophages will depend on a variety of factors, including the body weight of the subject being treated. By way of example, a therapeutically effective amount may be 1×10 7 From 1×10 9 In some embodiments, the dose may be in the form of a dose of 10 non-polarized macrophages. 7 , 10 8 or 10 9 Suitably, the treatment consists of three doses administered as an infusion monthly, i.e. approximately 10 9 The initial dose consists of three infusions of macrophages up to 100 mg / kg. Advantageously, the additional doses may allow further breakdown of scar tissue to occur. In one embodiment, all doses of macrophages administered to a patient will be harvested from a single leukapheresis collection. In some embodiments, the final dose administered may depend on the starting number of monocytes, ranging from 10 to 150 mg / kg, depending on the patient. 8 It can be a multiple of .
[0074] In some embodiments, macrophages according to the present invention may be provided in a suitable storage or transport bag.
[0075] Administration The macrophage product according to any aspect of the invention may be administered into the body of a recipient by any suitable means, including, but not limited to, percutaneous, subcutaneous, intramuscular, parenteral, enteral, intravenous, intraperitoneal, intraorbital, intraretinal, by tissue implantation and into the cerebrospinal fluid. Advantageously, the macrophage product is administered intravenously, such as, for example, by intravenous injection or infusion.
[0076] Previous studies have supported that portal vein delivery maximizes the number of cells delivered to the liver, but repeated portal vein administration in patients with cirrhosis carries the risk of portal hypertension and coagulopathy, making this delivery route undesirable in clinical settings.The present inventors have found that this delivery route is clinically effective, although the number of cells distributed to the liver is likely to be lower after intravenous injection.
[0077] In some embodiments, non-polarized macrophages for use according to the present invention are prepared in a pharma- ceutically acceptable carrier. The pharma- ceutically acceptable carrier may be any substance that allows for delivery of non-polarized macrophages to a subject and may include any suitable diluent or excipient or combination thereof. In some embodiments, non-polarized macrophages may be delivered in saline supplemented with a human albumin solution.
[0078] Thus, non-polarized macrophages for use in accordance with the present invention may be provided in a pharmaceutical composition comprising a therapeutically effective amount of the non-polarized macrophages and a pharma- ceutically acceptable carrier.
[0079] In suitable embodiments, the pharmaceutical composition of the present invention may further comprise pharma- ceutically acceptable concentrations of salts, buffers, and compatible carriers. The composition may also comprise an antioxidant and / or a preservative. In some embodiments, the pharmaceutical composition may comprise DMSO, e.g., 5-10% DMSO.
[0080] combination In some embodiments, macrophage therapy according to the present invention can be combined with another treatment for liver disease. Suitable treatments include treatment with G-CSF. In some embodiments, the other treatment can include antifibrotic drug treatment. Suitable antifibrotic drugs are reviewed, for example, by Wang et al. (Front Physiol. 2016; 7:47; doi:10.3389 / fphys.2016.00047) and Tacke et al. (J. Hepatology 2017; 66:1300-1312).
[0081] Various further aspects and embodiments of the present invention will be apparent to those skilled in the art in view of the present disclosure.
[0082] All documents mentioned in this specification are incorporated herein by reference in their entirety.
[0083] As used herein, "and / or" should be interpreted as a specific disclosure of each of the two specific features or components, whether or not the other is present. For example, "A and / or B" should be interpreted as a specific disclosure of (i) A, (ii) B, and (iii) each of A and B, as if each were independently set forth herein.
[0084] Unless the context dictates otherwise, the above feature descriptions and definitions are not limited to any particular aspect or embodiment of the invention, but apply equally to all aspects and embodiments described. EXAMPLES
[0085] Certain aspects and embodiments of the present invention will now be described, by way of example, with reference to the figures mentioned above.
[0086] Example 1 Optimization of GMP-compliant culture of monocytes Isolation of cells from healthy donors Donor buffy coats as a source of healthy donor monocytes were provided by the Scottish National Blood Transfusion Service (SNBTS) Blood Donor Centre, Edinburgh, UK, under SNBTS sample governance 13-12 and 14-02. CD14 selection from PBMCs: PBMCs were isolated from normal donor buffy coats by density centrifugation using Histopaque 1077 (Sigma). After washing, CD14+ monocytes were isolated from the mononuclear cell fraction using CliniMACS GMP grade CD14 microbeads and LS separation magnetic columns (Miltenyi Biotec). Briefly, cells were resuspended to the appropriate concentration in PEA buffer (phosphate-buffered saline [PBS] plus 2.5 mmol / L ethylenediaminetetraacetic acid [EDTA] and human serum albumin [Alburex 20% at 0.5% final volume, Octopharma]) and incubated with CliniMACS CD14 beads according to the manufacturer's instructions, then washed and passed through a magnetized LS column. After washing, purified monocytes were eluted from the demagnetized column, washed, and resuspended in the relevant medium for culture.
[0087] Isolation of cells from patients with liver cirrhosis For optimization and validation of the full-scale GMP process, peripheral blood mononuclear cells (PBMCs) were collected by leukapheresis at the Edinburgh Royal Hospital, SNBTS Clinical Apheresis Unit. Ethical approval was obtained from the South East Scotland Research Ethics Committee 02. Informed consent for apheresis transfusion was obtained in accordance with the Declaration of Helsinki. Isolation of CD14+ cells from leukapheresis: PBMCs were collected by leukapheresis from cirrhotic donors who granted informed consent to participate in the study. Eligibility criteria were an age range of 18 to 75 years, and cirrhosis was defined by any of the following: previous liver biopsy with confirmed histological features of cirrhosis, transient elastography (Fibroscan) >18 kPa, and / or clinical and radiological features that correlated with a diagnosis of cirrhosis in the opinion of the clinical director. For the purpose of the study, exclusion criteria included conditions requiring ongoing antiviral treatment such as viral hepatitis, average alcohol intake >21 units / week (men) or >14 units / week (women), ascites not adequately controlled with diuretic therapy in the past 3 months, encephalopathy requiring hospitalization for treatment in the past 3 months, portal hypertensive bleeding in the past 3 months, hepatocellular carcinoma, other cancers within the past 5 years, previous liver transplant or currently on the waiting list, presence of clinically relevant acute illnesses that may compromise safe presentation and pregnancy and / or breastfeeding. Leukapheresis of peripheral blood for mononuclear cells (MNC) was performed by aseptic collection using the Optia apheresis system. A standard collection program for MNC was used and 2.5 blood volumes were processed. Isolation of CD14 cells was performed using a GMP-compliant functionally closed system (CliniMACS Prodigy system, Miltenyi Biotec). Briefly, the leukapheresis product was sampled for cell counting and an aliquot was taken for pre-isolation flow cytometry. The percentage of monocytes (CD14+) and absolute cell numbers were determined and, if necessary, the volume was adjusted to meet the required criteria for selection (≤20 × 10 9 Total white blood cells: <400 × 10 6 White blood cells / mL; ≦3.5×10 9CD14 cells, volume 50–300 mL). Isolation and separation of CD14 cells was performed using a CliniMACS Prodigy (medical device class III) with CliniMACS CD14 microbeads, TS510 tube set, and LP-14 program. At the end of the process, selected CD14+ positive monocytes were washed with PBS / EDTA buffer (CliniMACS buffer, Miltenyi) containing pharmaceutical grade 0.5% human albumin (Alburex) and resuspended in TexMACS (or control) medium for culture.
[0088] Cell counting Cell counts of total MNC and isolated monocyte fractions were performed using a Sysmex XP-300 automated analyzer (Sysmex). As the Sysmex consistently underestimated macrophage numbers, assessment of macrophage numbers was performed by flow cytometry using TruCount tubes (Becton Dickinson) to determine absolute cell numbers. Purity of the isolation was assessed using a panel of antibodies against human leukocytes (CD45-VioBlue, CD15-FITC, CD14-PE, CD16-APC) using flow cytometry (FACSCanto II, BD Biosciences), and product quality was assessed by determining the amount of neutrophil contamination (CD45int, CD15pos).
[0089] Cell collection For macrophages from normal donors, cells were removed from the wells using Cell Dissociation buffer (Gibco, Thermo Fisher) and Pastet on day 7. Cells were resuspended in PEA buffer, counted, and approximately 10 cells were collected per experiment for flow cytometry. 6Cells were stained for 100 μg / mL. Leukapheresis-derived macrophages were removed from the culture bags on day 7 using PBS / EDTA buffer (CliniMACS buffer, Miltenyi) containing pharmaceutical grade 0.5% human albumin (HAS; Alburex) from serum. Collected cells were resuspended in a vehicle consisting of two licensed products: 0.5% human albumin (Alburex) with 0.9% saline for injection (Baxter).
[0090] Cell sorting efficiency Sorting efficiency using CD14 CliniMACS beads was very high and results were comparable for all methods, whether cells were sourced from buffy coats or from leukapheresis from cirrhotic patients; bead-labeled cells were manually labeled and isolated on LS columns or processed using the fully automated CliniMACS prodigy system. Presorting and flow cytometric analysis of positive and negative fractions showed a high enrichment of the positive fraction (95.9%) and minimal loss of the negative fraction (4.1%) from an initial mean of 20.5% monocytes in 26 different normal donor isolations using CliniMACS CD14 reagent and LS columns (Fig. 1A). Very similar figures were seen in cirrhotic donor samples isolated using CliniMACS Prodigy (Fig. 1B), although cirrhotic donors had a higher (albeit not significantly) initial mean percentage of monocytes in the collection (Fig. 1C).
[0091] Optimal medium for culturing monocytes from healthy donor samples We investigated the optimal culture medium for macrophage differentiation and tested three candidates using buffy coat monocytes; Dulbecco's Modified Eagle Medium (DMEM; Life Technologies) supplemented with 5% AB serum (SNBTS) and two chemically defined serum-free culture media, AIM-V (Thermo Fisher) and TexMACS (Miltenyi). TexMACs medium is an optimized serum-free cell culture medium optimized for the culture and expansion of human and mouse T cells and regulatory T cells, containing preselected human serum albumin, stable glutamine, and phenol red (not present in the clinical version). Experiments were performed with buffy coat monocytes cultured at 37 °C in a humidified atmosphere of 5% CO2 for 7 days with 100 ng / mL of premium grade macrophage colony-stimulating factor (M-CSF; Miltenyi) per medium. Cells were seeded in 6-well tissue culture plates at a density of 1.8 × 107 cells / well in 4 ml of medium and refed on days 3–4. Production of macrophages in AIM-V complete culture medium has been reported previously (Moore JK et al., Cytotherapy. 2015; 17(11):1604-16). However, the antibiotic content of this medium was not compatible with testing product sterility by assessment of bacterial growth, so antibiotic-free TexMACS complete medium was evaluated as a comparison medium. GMP-grade TexMACS culture medium consistently resulted in higher conversion rates to macrophages compared to AIM V, although this did not reach statistical significance (Figure 1D). Although culture in DMEM plus 5% AB serum also resulted in comparable macrophage conversion rates, DMEM-cultured macrophages also adhered strongly to the substrate, resulting in cell loss during collection (Figure 1G). Furthermore, monocytes cultured in TexMACS generated significantly larger macrophages as calculated using forward scatter from flow cytometry (Figure 1E). In early development experiments, we supplemented culture media with premium research grade M-CSF (Miltenyi) as previously used (Moore JK et al., Cytotherapy. 2015;17(11):1604-16).This was compared with GMP-grade M-CSF (R&D Systems), both at 100 ng / ml. There were no significant differences in morphology or macrophage yield when cultured with either source, but macrophages generated with GMP-grade M-CSF showed higher expression of the macrophage marker 25F9 (Figure 1F). TexMACS medium (Miltenyi) supplemented with GMP-grade M-CSF (R&D Systems) appeared to be the optimal medium for the production of GMP-grade macrophages.
[0092] Induction of macrophages from frozen monocytes Macrophage induction from fresh and frozen / thawed monocytes was also compared (see Results section). Monocytes were isolated from buffy coats, then an aliquot was frozen in cryopreservation medium (Cryostor CS10, Sigma) and the remainder was cultured fresh. Frozen aliquots were thawed after a few days and cultured as before.
[0093] For therapeutic applications, it is attractive to freeze aliquots of monocytes to generate multiple macrophage doses. We assessed whether there were significant differences in macrophage yield or phenotype that would preclude the use of frozen stocks. The data showed that there were differences in both yield and phenotype. Notably, there was a notable decrease in expression of CD206 and CD163 (Figure 2). There was also an inverse increase in CCR2 expression (Figure 2). This suggests that macrophages from frozen monocytes develop a classically activated phenotype, more similar to M1. Furthermore, in these experiments, the average viability of macrophages from thawed monocytes was significantly lower than fresh monocytes (viability 45.5% vs. 75.2% for fresh macrophages, n=4–6, P=0.0098). It was concluded that the low viability (and therefore yield) and less favorable phenotype preclude further development of macrophage products from frozen cells for early clinical use.
[0094] Example 2 Diastolic function analysis: healthy donor macrophages Phagocytic uptake by monocytes and macrophages Functional characterization of normal macrophages investigated the cells' ability to ingest particles. Both monocytes and macrophages from buffy coat CD14 cells were tested for phagocytic uptake using pHRodo beads, which only fluoresce when ingested into acidic endosomes. Briefly, monocytes or macrophages were incubated with 1-2 uL of pHRodo E. coli bioparticles (Life Technologies, Thermo Fisher) for 1 h, after which the medium was removed and cells were washed to remove non-phagocytosed particles. Phagocytosis was assessed using an EVOS microscope (Thermo Fisher), images were acquired, and cellular uptake of beads was quantified using ImageJ software (NIH freeware, https: / / imagej.nih.gov / ij). The use of pHRodo beads in these studies allows for an accurate assessment, as the beads are transparent until phagocytosed and exposed to the acidic environment of the phagolysosome, where they fluoresce. Phagocytosis was quantified from EVOS images (Figure 3A), assessing the total number of cells per field, the total number of cells containing fluorescent beads, and the number of beads per cell. Quantification of phagocytosis using this method demonstrated no difference between monocyte and macrophage uptake (Figure 3B). Further analysis showed that stimulation of macrophages with TNF-α and poly I:C did not significantly affect phagocytosis (data not shown).
[0095] Macrophage polarization upon harvest Phenotypic analysis showed that macrophages at harvest were not polarized, although they demonstrate high CD206 and CD169 expression characteristic of alternatively activated macrophages (Figure 6). IFN-γ and IL-4 stimulation were used to determine whether macrophages at harvest were capable of responding to polarizing cytokine exposure. The ability to polarize into defined differentiated macrophages was investigated by treating day 7 macrophages with interferon (IFN)-γ (50 ng / mL) or interleukin (IL)-4 (20 ng / mL) for 48 hours to induce polarization into M1 or M2 phenotypes (or M[IFNγ] vs. M[IL-4], respectively). After 48 hours, cells were visualized with an EVOS brightfield microscope and harvested and phenotyped as before. At day 2 of polarization, there were morphological differences in the cultures, with IFN-γ-treated macrophages exhibiting a curved, angular shape (Figure 4A), while IL-4-treated macrophages displayed a characteristic spindle-shaped morphology. Although there was no significant difference in 25F9 marker expression between the cultures, IL-4 treated cells were able to significantly upregulate CD206, which is characteristic of polarized M2a macrophages (Figure 4B). This polarization is characteristic of macrophages in vitro and does not necessarily predict functional capacity in the recipient.
[0096] Macrophage cytokine and growth factor secretion profile The final aspect of cell product evaluation was the determination of resting and stimulated macrophage factor secretion profiles (Figure 5). Macrophages were generated from healthy donor buffy coats as before and were either left untreated or stimulated with tumor necrosis factor (TNF)-α (50 ng / mL, Peprotech) and polyinosinic:polycytidylic acid (Poly I:C, a viral homolog that binds to TLR3, 1 _g / mL, Sigma) to mimic conditions present in inflamed liver, or stimulated with lipopolysaccharide (LPS, 100 ng / mL, Sigma) and IFN-γ (50 IU / mL, Peprotech) to generate maximal macrophage activation. Day 7 macrophages were incubated overnight and the supernatants were harvested, centrifuged to remove debris, and stored at -80°C until testing. Secretome analysis was performed using a 27-plex human cytokine kit and a 9-plex matrix metalloproteinase kit and was performed on an aMagpix multiplex enzyme-linked immunoassay plate reader (BioRad). At rest, macrophages expressed low levels of IL-1Ra, IL-10 and vascular endothelial growth factor (VEGF). To mimic an inflammatory environment, stimulation with TNF-α and poly I:C was used, which significantly increased the production of the pro-regenerative / anti-inflammatory factors VEGF, IL-10 and IL-1Ra, but not IL-12. LPS / IFN-γ stimulation did not strongly increase the expression of IL-10, whereas conversely, IL-12 expression was strongly increased by LPS / IFN-γ. TNF-α / poly I:C stimulation increased the expression of CCL3, 4 and 5, but not CCL2. Macrophages constitutively expressed high levels of MMPs 7, 9, and 12, and low expression of MMP3, which was not significantly regulated after stimulation or polarization, and expression of MMPs 1, 7, 8, 10, and 11 was negligible (data not shown).
[0097] Example 3 Process verification for patients with liver cirrhosis Culturing monocytes from patient samples
[0098] Monocytes cultured from leukapheresis from Prodigy isolation were cultured in culture bags (MACS GMP differentiation bags, Miltenyi) with GMP grade TexMACS (Miltenyi) and 100 ng / mL M-CSF, with a volume of 1 cm 2 and 2 x 10 per mL 6 Monocytes were cultured with 100ng / mL GMP-compliant recombinant human M-CSF (R&D Systems). Cells were cultured for 7 days at 37°C in a humidified atmosphere of 5% CO2. During the culture, two 50% volume medium replenishments were performed (on days 2 and 4) by removing 50% of the culture medium (to restore the final concentration to 100ng / mL) and providing fresh medium supplemented with 200ng / mL M-CSF.
[0099] Process Validation Cell culture and identification data were used to design and validate the GMP process. A set of markers were selected from a broad phenotypic panel to use as product release criteria, including cell identification and functional markers. These were expression of CD45 and CD14 for lineage commitment and expression of 25F9 as a marker of macrophage maturity. Additionally, CD206 was selected as a surrogate marker of phagocytosis and purifying capacity, effectively identifying the development of proper functional macrophages. The viability stain DRAQ7 was included as the final component of the GMP release criteria panel. For further information on the cell product, a second phenotypic set, called the extended panel, was used, evaluating expression of CD163, CD169, and CCR2. This panel was validated on leukapheresis donations from seven cirrhotic volunteers.
[0100] Expression of cell surface markers of monocytes and macrophages was analyzed using either a FACSCanto II (BD Biosciences) or a MACSQuant 10 (Miltenyi) flow cytometer. Approximately 20,000 events were acquired for each sample. Cell surface expression of leukocyte markers in freshly isolated and day 7 mature cells was performed by incubating cells with specific antibodies (final dilution 1:100). Cells were incubated with FcR block (Miltenyi) for 5 min followed by incubation with antibody cocktail for 20 min at 4°C. Cells were washed with PEA and the dead cell exclusion dye DRAQ7 (BioLegend) was added at 1:100. Cells were stained with various surface markers: CD45-VioBlue, CD14-PE or CD14-PerCPVio700, CD163-FITC, CD169-PE and CD16-APC (all Miltenyi), CCR2-BV421, CD206-FITC, CXCR4-PE and CD115-APC (all BioLegend), and 25F9-APC and CD115-APC (eBioscience). Both monocytes and macrophages were gated to exclude debris, doublets and dead cells using forward and side scatter and a DRAQ7 dead cell discriminator (BioLegend) and analyzed using FlowJo software (Tree Star). From the initial detailed phenotype, a panel was developed as the release criteria (CD45-VB / CD206- FITC / CD14-PE / 25F9-APC / DRAQ7) that defined the development of functional macrophages from monocytes. Macrophages were determined to have a mean fluorescence intensity (MFI) for both 25F9 and CD206 that was 5-fold higher than the levels of monocytes on day 0. A second panel was developed to evaluate other markers as part of an expansion panel, consisting of CCR2-BV421 / CD163-FITC / CD169-PE / CD14-PerCP-Vio700 / CD16-APC / DRAQ7, but was not used as part of the cell product release criteria.
[0101] CD14+ cells were selected using a CliniMACS Prodigy device and cells were cultured as described above. Expression levels of each marker are shown in Figure 6 for enriched monocytes at day 0 and corresponding macrophages at day 7. Differentiated cells retained CD45+ CD14+ expression, and 25F9, CD206, CD169 and CD163 were significantly elevated in macrophages. Compared to monocytes, CCR2 becomes significantly downregulated in macrophages. The migratory capacity of macrophages after collection was also assessed using a transwell chemotaxis assay to confirm that they retained the ability to migrate to appropriate targets in vitro despite downregulation of CCR2 (data not shown).
[0102] Stability of monocytes after collection from patients with cirrhosis Stability studies were performed on macrophages stored in the optimal excipient (clinical grade 0.9% saline with 0.5% HAS) determined during process optimization at controlled room temperature (21-22 °C). Various excipients were tested during process development, including PBS / EDTA buffer with 0.5% HAS (Alburex), 0.9% saline only, or saline with 0.5% HAS. 0.9% saline with 0.5% HAS excipient (Baxter) was found to maintain optimal cell viability and phenotype (data not shown). Stability of macrophages from cirrhotic donors after collection was investigated in three process optimization runs and a more limited range of time points was evaluated in a process validation run (n=3). After harvest and resuspension in vehicle (0.9% Saline for Injection, 0.5% Human Serum Albumin), bags were stored at room temperature (21-22°C) and samples were taken at 0, 2, 4, 6, 8, 12, 24, 30 and 48 hours after harvest. A release benchmark antibody panel was run on each sample and viability and mean fold change from day 0 were measured from the geometric MFI of 25F9 and CD206. After sampling at each time point, cells were assessed for phenotype and viability. Data from all three process optimization runs were analyzed for cell viability and phenotype (25F9 / CD206 Both the MFI and CD406 MFI were shown to be maintained for 48 hours after harvest (Figure 7), indicating that the process reproducibly generates a highly stable cell product. Thus, release criteria were established that macrophages must be CD45 / CD14 positive, have a viability of over 80%, and have MFIs for 25F9 and CD206 that are 5-fold higher than the MFI of the original monocytes on day 0. All final results of the release criteria process validation, including stability, are listed in Table 1.
[0103] [Table 1]
[0104] Particulars include the parameters used as release criteria for the final product.
[0105] Example 4 Autologous monocyte-derived macrophage therapy for human trials A. Single Ascending Dose (SAD) Phase I Clinical Trial Patient recruitment Eligibility criteria were age range of 18 to 75 years, MELD range of 10.00 to 16, and cirrhosis defined by any one of the following: alcohol-related liver disease (ALD), primary biliary cirrhosis (PBC), nonalcoholic fatty liver disease (NAFLD), cryptogenic cirrhosis, hemochromocytosis, α-1-antitrypsin deficiency, or treated (sustained viral response) hepatitis C. Exclusion criteria were portal hypertensive bleeding in the past 3 months, ascites not adequately controlled with diuretic therapy in the past 3 months, brain disease requiring hospitalization for treatment in the past 3 months, hepatocellular carcinoma (excluding hypoplastic or indeterminate nodules, including regenerative or other nodules), previous diagnosis of hepatocellular carcinoma, previous organ transplant recipient or previous tissue recipient. Other exclusion criteria included: alcohol or drug abuse, residence far from the study site, noncompliance or lack of cooperation, clinically relevant acute illness that would interfere with study participation, presence or history of cancer within the past 5 years, and pregnancy or breastfeeding.
[0106] [Table 2A]
[0107] [Table 2B]
[0108] Autologous non-polarized macrophage products CD14+ monocytes are isolated from the leukapheresis product using the CliniMACS Prodigy® closed system. CD14+ monocytes are cultured for 7 days in low-adherence culture bags (Miltenyi) in the presence of TexMACS™ serum-free medium (Miltenyi) and 100 ng / ml M-CSF (R&D Systems) as described above. 33% medium changes are performed on days 3 and 5. Additionally, the end product is assessed for markers of macrophage phenotype (25F9 and CD14) and function (CD206). Viability assessment is performed by DRAQ7 staining as described above. The end product is collected and cultured at ≦1×10 6 cells in 125 mL of 0.9% saline (Baxter) and 0.5% human albumin solution. 7 ;≦1x10 8 or ≦1x10 9 The cells are prepared as a population for infusion and the product is placed into a transfer bag (Terumo 150 mL transfer bag), overwrapped, and shipped to the investigator's site for use within 48 hours.
[0109] research design The first phase of the study will be designed as a standard 3+3 design to test cell safety and tolerability in humans. Autologous macrophages will be administered in one injection at three different cell doses; 10 7 , 10 8 , 10 9 Participants will receive cells in an escalating dose regimen using a 1:1 ratio. Each dose of cells will be administered to three participants. After macrophages have differentiated from monocytes on day 7 after apheresis, participants will return to the clinical research unit. Prior to administration of the autologous macrophage product, participants will receive 10 mg IV chlorphenamine, 100 mg IV hydrocortisone, and 250 ml of normal saline via an intravenous cannula over 30 minutes. The macrophage product will be administered intravenously over 30 minutes, followed by an infusion of 250 ml of normal saline over 15-20 minutes. Blood tests will be performed on participants 7 and 14 days after the infusion, and then at 30, 60, 90, 180, and 360 days.
[0110] Regenerating macrophages in patients with liver cirrhosis It has been demonstrated that regenerative macrophages can be derived from patients with cirrhosis. There was no significant difference in the gene expression of several markers, including CCL2, MMP9, IL10, and CCL3, in ex vivo differentiated macrophages from healthy and cirrhotic patients (Figure 8).
[0111] In the MATCH study, MELD was measured at various time points. The first measurement was taken 3-6 months prior to initial screening. This data point is called d-120, but each patient's actual blood tests were taken at different time points within the 3-6 month period. MELD was also measured at initial screening, i.e. baseline (d-14), and then at d7, d14, d30, d60, d90, d180, and d360. d0 is the day of administration of macrophage products.
[0112] MELD consists of three components; bilirubin (BIL), creatinine (CRE), and the international normalized ratio (INR), which are combined using the following formula to generate the MELD score:
[0113] MELD=10*[(0.957*In(CRE(mmol / l)*0.011312217))+(0.378*In(BIL(mmol / l)*0.058479532))+(1.12*In(INR))]+6.43 (Huo et al., Journal of hepatology 2005; 42(6):826-32).
[0114] None of the components of MELD can have a negative contribution, and the MELD score is rounded to the nearest integer. Table 3 shows the MELD data for all subjects in the MATCH study. ΔMELD for all patients was calculated relative to baseline (d-14), with negative values indicating an improvement in clinical status. Figure 9 shows the mean ΔMELD for all patients. The most notable response is from S05, where a transient decrease in MELD of 6 points was observed. Macrophage therapy is thought to have a greater effect on patients with cirrhosis whose underlying etiology is caused by hepatocytes. Since the etiology of patient S04 was primary biliary cholangitis (PBC), which is not thought to be due to hepatocytes, it is not surprising that a lesser response to treatment was observed in this patient. Respond.
[0115] To understand the mechanistic contribution of nonpolarized macrophage therapy to ΔMELD, the contribution of each component of MELD to ΔMELD was evaluated and illustrated as shown in Figure 10. The results suggest that MELD scores are reduced in two of the three components; BIL and INR, with 62% of the variance in ΔMELD explained by the contribution of BIL and the remainder from INR. No significant changes in MELD scores were observed for the contribution of the CRE components. These results suggest that the improvement observed in MELD is due to a direct improvement in liver function. Bilirubin is a by-product of hemoglobin metabolism as a result of the death of red blood cells. Circulating bilirubin is glucuronidated by hepatocytes and then excreted via the bile duct. Thus, BIL is a measure of hepatocyte health and function. INR is a result of the liver's ability to synthesize vitamin K-derived clotting factors and is a less direct measure of hepatocellular function than BIL, but also suggests improved liver health. In contrast, CRE is a renal marker and a surrogate for multiple organ failure associated with cirrhosis. Thus, our data indicate that nonpolarizing therapy not only has a beneficial effect on MELD, but that this effect is mediated by improved liver function, consistent with the proposed mechanism of action of the treatment.
[0116] [Table 3A]
[0117] [Table 3B]
[0118] Also in the MATCH study, enhanced liver fibrosis (ELF), which provides a non-invasive measurement of fibrosis, was measured at various time points including screening (d-14), d30, d60, d90, d180, and d360. d0 is the day of administration of macrophage products. Figure 11 shows the ELF scores for all patients in the MATCH study, Figure 12 shows the ΔELF for all patients in the MATCH study, and Figures 13, 14, and 5 show the analysis of each component of the ELF score - HA values, PNIIIP, and TIMP1, respectively. The graphs show the overall reduction in enhanced liver fibrosis measured over the 360 days.
[0119] The precisely cleaved N-terminal propeptide of collagen type III (PRO-C3) and peptides of helical collagen type III cleavage (C3M) were measured at various time points including at screening, screening (d-14), d30 and d90.
[0120] [Table 4]
[0121] The PRO-C3 data indicate a reduction in fibrosis formation.
[0122] [Table 5]
[0123] B. Phase II Trials A randomized controlled trial will be conducted. 28 participants will be randomized to receive standard medical care. The 28 participants will receive 10 9Receive a total of three injections of macrophages.
[0124] Autologous non-polarized macrophage products Monocytes cultured from leukapheresis from Prodigy isolation were cultured in culture bags (MACS GMP differentiation bags, Miltenyi) with GMP grade TexMACS (Miltenyi) and 100 ng / mL M-CSF, with a volume of 1 cm 2 and 2 x 10 per mL 6 Monocytes were cultured with 100ng / mL GMP-compliant recombinant human M-CSF (R&D Systems). Cells were cultured for 7 days at 37°C in a humidified atmosphere of 5% CO2. During the culture (day 4), one 50% volume medium refill was performed in which 50% of the culture medium was removed and fresh medium supplemented with 200ng / mL M-CSF (to return to a final concentration of 100ng / mL). Advantageously, this single feed reduces cell manipulation and handling steps (compared to two feeds), resulting in reduced costs as well as reduced cell loss.
[0125] As described above, CD14+ monocytes are isolated from the leukapheresis product and characterized prior to shipping to the investigator's site.
[0126] Measurement results: Injected patients will have their outcome assessed by one or more of the following assessments / measurements; MELD and Delta MELD; UKELD and Delta UKELD; Transient Elastography (Fibroscan™, Echosens, France) (Fraquelli et al., Gut, 2007; 56(7):968-73) - a non-invasive assessment of liver fibrosis at screening, 90, 180 and 360 days; Enhanced Liver Fibrosis (ELF) test - ELISA assays for enzymes involved in matrix components and their turnover (hyaluronic acid, tissue inhibitor of matrix metalloproteinase 1 (TIMP-1), procollagen type III (PIIINP) calculated ELF score for levels of liver fibrosis; 31-P-MRS and liver MRI scans: a non-invasive and quantitative measurement of liver metabolic and regenerative activity at random and 90 days after treatment; MRI of liver volume and blood flow. Other methods of assessing outcome include the CLDQ (Chronic Liver Disease Questionnaire) (Younossi et al., Gut 1999; 45(2); 295-300) and those described by Newsome et al., Gastroenterol Hepatol. 2018; 3:25-36.
[0127] Additional analyses may include measuring changes in protein markers: During turnover of the extracellular matrix (ECM), proteolytically cleaved matrix degradation fragments, or neoepitopes, are released into the systemic circulation. Cleavage of each ECM protein by specific MMPs generates unique neoepitopes. These neoepitopes may be more accurate diagnostic and prognostic markers for an individual's fibroproliferative disease than their original proteins. Methods to detect such specific protein fragments and identify and quantify disease include Protein Fingerprint™ technology (Nordic Bioscience). These new serum biomarkers have been shown to identify patients with advanced fibrosis, allow monitoring of response to antifibrotic therapy, and also correlate with portal hypertension in patients with cirrhosis. [References] TIFF2024166223000008.tif201161TIFF2024166223000009.tif218160TIFF2024166223000010.tif185161TIFF2024166223000011.tif116161
Claims
1. Autologous isolated non-polarized human macrophages for use in the treatment of liver disease.
2. 2. Autologous isolated non-polarized human macrophages for use according to claim 1, wherein said macrophages are of monocyte origin.
3. 3. Autologous isolated non-polarized human macrophages for use according to claim 1 or 2, wherein the macrophages are mature macrophages.
4. 4. Autologous isolated non-polarized human macrophages for use according to any one of claims 1 to 3, wherein said macrophages are characterized by elevated expression of at least one of surface 25F9 or CD206 that is at least 5-fold compared to expression in macrophage source cells.
5. 5. Autologous isolated non-polarized human macrophages for use according to claim 4, wherein said macrophages are further characterized by increased expression of one or more of CD163 and CD169.
6. 6. Autologous isolated non-polarized human macrophages for use according to any one of claims 1 to 5, wherein said non-polarized macrophages are prepared from CD14+ monocytes isolated from peripheral blood of a diseased patient.
7. 7. Autologous isolated non-polarized human macrophages for use according to claim 6, wherein the CD14+ monocytes are incubated with M-CSF at a concentration of 100 ng / ml for 7 days.
8. A macrophage for use in a method of treating fibrosis in a human in need thereof.
9. The macrophage of claim 8 for treating fibrosis by administering one or more doses of said macrophage to a human in need thereof.
10. 10. The macrophage of claim 8 or 9, wherein the macrophage is derived from the human's own PBMCs, healthy donor PBMCs, or stem cells including bone marrow, embryonic stem cells or induced pluripotent stem cells.
11. The macrophage of claim 10, wherein the macrophage is not polarized.
12. 12. The macrophage of claim 11, wherein the one or more doses are administered at intervals of approximately 30 days.
13. 13. The macrophage according to any one of claims 8 to 12, wherein a human in need thereof has liver cirrhosis, preferably a sclerosing liver disease.
14. 14. The macrophage of any one of claims 1 to 13, wherein the human in need thereof is an affected patient with a MELD score of 10 to 16.
15. 1. A macrophage for use in a method of treating fibrosis by administering three doses to a human in need thereof, the first dose being administered on day 1, the second dose on day 30, and the third dose on day 60.
16. 16. Autologous isolated non-polarized human macrophages according to any one of claims 1 to 7 or macrophages according to any one of claims 8 to 15 for use by intravenous administration.
17. 1×10 7 From 1×10 9 17. Autologous isolated non-polarized human macrophages according to any one of claims 1 to 7 or macrophages according to any one of claims 8 to 16 for use by administration of one or more doses comprising said macrophages.
18. Autologous isolated non-polarized human macrophages for use according to any one of claims 1 to 7 or the macrophages according to claim 13, wherein the liver disease is cirrhosis, preferably the cirrhosis is caused by either high alcohol consumption, obesity, metabolic disorders or viral infection, most preferably alcohol-induced cirrhosis, NASH or HCV.
